Core Insights - The National Medical Insurance Administration has revealed typical cases of drug tracing codes to combat the issue of returned drugs, highlighting the effectiveness of digital technology in regulatory enforcement and the government's firm stance against this illegal practice [1][2] Group 1: Overview of Returned Drugs - Returned drugs refer to pharmaceuticals that have been illegally retrieved from the legitimate medical distribution channels and reintroduced into the market, posing significant risks to public health and disrupting market order [1] - Illegal activities include enticing insured individuals to resell medical insurance drugs and repackaging expired drugs for resale, which undermines the integrity of the pharmaceutical market and threatens the safety of drug use [1] Group 2: Technological Advancements in Regulation - The implementation of drug tracing codes is changing the landscape of drug regulation, allowing for the identification of multiple sales scan records for a single drug package, which may indicate returned or counterfeit drugs [1] - A societal consensus has emerged around the necessity of scanning drugs before purchase and sale, further reducing the space for returned drugs to operate [1] Group 3: Challenges and Solutions in Governance - Addressing the issue of returned drugs requires a multifaceted approach, including increasing the legal consequences for offenders and enhancing collaboration among various regulatory bodies [2] - Establishing a unified data standard and a data-sharing mechanism among departments such as medical insurance, health, and market regulation is essential for improving oversight and governance efficiency [2] - Active participation from pharmacies and consumers in reporting returned drugs is crucial for fostering a safe and compliant pharmaceutical distribution environment [2]

Core Viewpoint - The National Medical Insurance Administration has showcased the effectiveness of "code-based supervision" in combating the illegal circulation of drugs, particularly focusing on the issue of "returned drugs" which are resold through illicit channels after being repackaged or having their information altered [1] Group 1: Regulatory Measures - From July 1, all medical insurance designated institutions are required to scan the unique "electronic ID" traceability code of each drug box during sales, ensuring traceability of drug sources and destinations [1] - The initiative aims to eliminate returned drugs and associated fraudulent insurance claims by enhancing the monitoring of drug traceability codes [1] Group 2: Future Actions - There is a call for further strengthening of drug traceability code supervision and rigorous investigation of abnormal medical insurance card drug purchases [1] - The plan includes enhancing inter-departmental joint law enforcement to impose severe penalties on drug traffickers and medical institutions involved in the illicit drug trade [1] - Raising public legal awareness is also emphasized to establish a robust safety barrier for the public's medication [1]

Core Viewpoint - The National Medical Insurance Administration has launched a campaign to combat the illegal sale and circulation of counterfeit drugs, emphasizing the importance of drug traceability to ensure public health and safety [1][2]. Group 1: Drug Traceability and Regulation - The campaign showcases the effectiveness of "code-based supervision" in tackling the issue of counterfeit drugs, which are often sourced through illegal channels and pose significant health risks to patients [1]. - Starting from July 1, all medical insurance designated institutions are required to scan the unique "electronic ID" traceability code of each drug box, allowing for tracking of drug sources and destinations [1]. Group 2: Challenges and Responsibilities - Despite the regulatory efforts, some illegal actors continue to profit from the distribution of non-compliant drugs, indicating that a comprehensive approach is necessary to eliminate the entire chain of illegal activities [2]. - Pharmaceutical companies, medical institutions, and retail pharmacies must adhere to strict drug sales management to prevent drugs from entering non-regulated channels, while the public should be aware of the risks and refrain from participating in the illegal sale of medical insurance drugs [2].